Overview

Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children

Status:
Recruiting
Trial end date:
2023-08-17
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to explore the therapeutic effect of eluxadoline in treating irritable bowel syndrome with diarrhea (IBS-D) in pediatric participants 6-17 years of age, to evaluate the pharmacokinetics of eluxadoline in pediatric participants with IBS-D, and to evaluate the safety and tolerability of eluxadoline in pediatric participants with IBS-D.
Phase:
Phase 2
Details
Lead Sponsor:
Allergan
Treatments:
Eluxadoline